Uptravi

The recommended starting dose of Uptravi (Selexipag) is 200 μg taken by mouth, 2 times a day. The doses should be spaced approximately 12 hours apart. Gradually, your doctor will increase your dose until you reach a dose that is effective without too many side effects. The maximum dose of Uptravi (Selexipag) is 1,600 μg taken 2 times daily.

Uptravi (Selexipag) may be taken with or without food. Taking the medication with food may reduce the severity of side effects. Swallow the tablets whole, with water. Do not split, crush, or chew the tablets.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.

It is important to take Uptravi (Selexipag) exactly as prescribed by your doctor. If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is less than 6 hours until your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.

If you miss taking your medication for 3 days or more, contact your doctor for directions on how to restart the medication. You may need to restart your treatment at a lower dose.

Store Uptravi (Selexipag) in its original package at room temperature, protect it from light and moisture, and keep it out of the reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

200 μg
Each round, light yellow, film-coated tablet with "2" debossed on one side contains 200 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide yellow (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

400 μg
Each round, red, film-coated tablet with "4" debossed on one side contains 400 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide red (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

600 μg
Each round, light violet, film-coated tablet with "6" debossed on one side contains 600 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide black (E172), iron oxide red (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

800 μg
Each round, green, film-coated tablet with "8" debossed on one side contains 800 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide black (E172), iron oxide yellow (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

1000 μg
Each round, orange, film-coated tablet with "10" debossed on one side contains 1,000 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide red (E172), iron oxide yellow (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

1200 μg
Each round, dark violet, film-coated tablet with "12" debossed on one side contains 1,200 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide black (E172), iron oxide red (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

1400 μg
Each round, dark yellow, film-coated tablet with "14" debossed on one side contains 1,400 μg of Uptravi (Selexipag). Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide yellow (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

1600 μg
Each round, brown, film-coated tablet, with "16" debossed on one side contains Uptravi (Selexipag) 1,600 μg. Nonmedicinal ingredients: carnauba wax, corn starch, D-mannitol, hydroxypropyl cellulose, hypromellose, iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), low substituted hydroxypropyl cellulose, magnesium stearate, propylene glycol, and titanium dioxide (E171).

Do not take Uptravi (Selexipag) if you:

• are allergic to Uptravi (Selexipag) or any ingredients of the medication
• are taking the medication Gemfibrozil

There may be an interaction between Uptravi (Selexipag) and any of the following:

• Clopidogrel
• Deferasirox
• fluconazole
• gemfibrozil
• Leflunomide
• lopinavir
• lumacaftor and Ivacaftor
• mifepristone
• rifampin
• ritonavir
• Teriflunomide
• Valproic acid

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

• stop taking one of the medications,
• change one of the medications to another,
• change how you are taking one or both of the medications, or
• leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with Uptravi (Selexipag). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Uptravi (Selexipag).

Liver function: Liver disease or reduced liver function may cause Uptravi (Selexipag) to build up in the body, causing side effects. If you have liver problems, discuss with your doctor how Uptravi (Selexipag) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Uptravi (Selexipag), and whether any special monitoring is needed. Your doctor may want to test your liver function regularly with blood tests while you are taking Uptravi (Selexipag). People with severely decreased liver function should not use Uptravi (Selexipag).

Low blood pressure: Uptravi (Selexipag) can cause low blood pressure to become worse. If you have any conditions that may be affected by decreased blood pressure, such as taking blood pressure medications, having low blood pressure, dehydration, or certain heart conditions, discuss with your doctor how Uptravi (Selexipag) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Uptravi (Selexipag), and whether any special monitoring is needed.

Thyroid problems: Some people taking Uptravi (Selexipag) develop changes in the function of their thyroid. Symptoms of these changes include feeling cold or hot all the time, a change in weight (gain or loss) without a change in your diet or amount of exercise you get, or feeling emotional. Contact your doctor if you experience these symptoms.

Pregnancy: Uptravi (Selexipag) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Uptravi (Selexipag), contact your doctor immediately.

Breast-feeding: It is not known if Uptravi (Selexipag) passes into breast milk. If you are a breast-feeding mother and are taking Uptravi (Selexipag), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

Children: The safety and effectiveness of using Uptravi (Selexipag) have not been established for children.